Myocardial Protection Systems
Schedule a Demo »
Smarter Myocardial Protection™ with the MPS® 3
Next Level Technology
Cardioplegia delivery and cardiac activity are now visually connected with the MPS® 3 Myocardial Protection System. The Quest™ MPS® System's coordinated drug delivery technology is well-known for eliminating patient dilution and the associated sequela caused by cardioplegia delivery. This technology has been proven beneficial for improved patient outcomes as well as a sound investment for hospitals.
Our engineers, working closely with perfusionists and surgeons, have designed the Quest™ MPS® 3 System with unique functionality to help ensure good aortic valve closure, quick arrest, and good flow distribution. These elements are essential in attaining an effective induction dose and sustained myocardial protection.
Discover how the Quest™ MPS® 3 System provides more control, accuracy, safety, and flexibility.
Mitigate Risk of M. Chimaera
Cardioplegia Confidence Using the MPS® 3 ND
Remove residual water from your cardioplegia circuit with our No Disinfection technology. Our state-of-the-art technology with dripless connectors removes water from the MPS® System. The absence of water, traditionally used to thermoregulate your patient's cardioplegia circuit, mitigates risk of M. Chimaera contaminating the cardiac O.R. sterile field.
ND Technology Cost Savings:
- Average annual disinfection cost: $7,000 per unit1
- $28,219 average SSI cost/incident2
About M. Chimaera
M. Chimaera is a slow-growing bacterium that is part of a group called non-tuberculous mycobacterium (NTM) commonly found in water. Annually, more than 250,000 heart bypass procedures are performed utilizing devices associated with these infections.3
Better Patient Care & Outcomes
Experience Control & Precision for Surgeons & Perfusionists
The Quest™ MPS® 3 ND System allows surgeons and perfusionists to take myocardial protection to the next level. Experience enhanced safety, precision, accuracy, and control with MPS® technology.
Enlarge Image
Experience the evolution of control and accuracy.
The Quest™ MPS® 3 ND System is redefining the induction dose of antegrade cardioplegia. With the touch of a button, you engage the auto-start feature. Auto-start is an innovative technology for myocardial protection, allowing for rapid closure of the aortic valve and commanding a faster arrest, while maximizing cardioplegia distribution and reducing time in the operating room.
Enlarge Image
Any ratio, any strategy, any methodology - any time.
All parameters are easily and quickly adjustable during the case, providing accurate and agile control for better myocardial protection.
The MPS® 3 ND enables perfusionists to collect and review data and analytics anytime throughout or after a procedure.
The Quest™ MPS® 3 ND System captures and records all drug volumes and concentrations in real time. The agility of the system allows for changes any time during the procedure. The console and freestanding controller work in unison to provide accurate and safe delivery of arrest and additive agents, no matter which cardioplegia protocol you prefer.
Enlarge Image
The Quest™ MPS® 3 system is a powerful tool for the cardiovascular team, and with detailed data analytics, promotes better patient care.
Enlarge Image
The MPS® 3 ND has an intuitive Active Monitoring Controller (AMC), allowing you to stay ahead of critical moments. The AMC provides a snapshot of critical information to the perfusionists, giving them a command center for control.
- Avoid medication errors with organized drug records
- Know the precise drug concentrations given to your patient in real time
- Increase patient safety
The MPS® 3 ND System is equipped with instructional safety alerts/alarms that display on the AMC, guiding the perfusionist to a quick resolution. Plus, with an internal battery, you will experience seamless power, regardless of external conditions.
Microplegia Versus Traditional Cardioplegia4
5.25% Reduction
In Adverse Events
13% of Patients
1 Day Less
20% Discharge
1 Day Earlier
$192 Reduction
In Medication Costs
$1,231 Reduction
In Hospital Costs
Microplegia Confidence
With the MPS® 3 System
Microplegia is superior myocardial protection without hemodilution. Only MPS® technology delivers precision microplegia by independent control of additive and arrest agents.
Figure A: Precision Drug Delivery Without Hemodilution5
Benefits of microplegia:
- Provides superior myocardial protection with natural distribution
- Maximizes aerobic environment for the myocardium
- Reduction of hemodilution
- Lowers transfusion rates
- Minimizes use of hemoconcentrator
- Reduces inotropes/blood products
Figure B: Diluted Cardioplegia5, traditional 4:1 (Blood:Crystalloid)
Negative effects of using crystalloid:
Excessive dilution may lead to...
- Tissue edema
- Increased use of blood transfusions
- A low HCT
- Elevated glucose levels
- Low cardiac output syndrome6
- Increased potassium levels
Value-Added Benefits for Rx & Admin
Improving Patient Safety While Reducing Costs
The Quest™ MPS® 3 ND technology can benefit hospitals at multiple levels through the next generation of myocardial protection. The advanced technology can reduce hospital costs and simplify pharmacy management.
Benefits of Quest™ MPS® technology that can improve the bottom line:
The Quest™ MPS® 3 ND System is proven to reduce adverse events with a faster recovery.
Enlarge Image
The Quest™ MPS® 3 ND System is a safe and reliable cardioplegia delivery system. With monitoring capabilities at the fingertips of the perfusionist, precision and accuracy are unmatched by any other system. For peace of mind, there is an internal backup battery in case of a facility power outage.
Key data is captured and stored on the controller. This information is available to further identify and evaluate trends for continuous improvement.
Enlarge Image
Hospitals can benefit by investing in the Quest™ MPS® 3 ND System by:
- Eliminating the purchasing of compound cardioplegia
- Reducing waste
- Improving patient outcomes
The innovative design of the Quest™ MPS® 3 ND System allows drawing drugs directly from the vial, which eliminates the need for compounding multi-ingredient cardioplegia solutions and can reduce waste.
With the superior myocardial protection that microplegia offers using the Quest™ MPS® technology, patients can benefit from a quicker recovery and less time in ICU.7
In addition to eliminating the need for compounding cardioplegia drugs, the Quest™ MPS® 3 ND System can assist with drug tracking and accuracy. Each individual case saves the protocols used during the procedure including drug lists and dosage amounts. The Quest™ MPS® 3 ND System can interface directly with hospital files to assist with tracking and usage of drugs. The data can be downloaded via a removable flash drive that can be imported into a spreadsheet.
Heat Exchanger Delivery Sets
Achieve Cooler Temperatures, Faster
The new MPS® 16-core heat exchanger delivery sets deliver cardioplegia at cooler temperatures more efficiently across all delivery flow rates and offer an additional access port to bolus or sample.
To retrofit an existing MPS® 2 system console for the new 16-core heat exchanger, please order an MPS® 2 locking block conversion kit (cat no. 5001032). It's easy to install, and will allow the MPS® 2 console to accept both the 10-core and 16-core heat exchangers.
Schedule a Demo
The Quest™ MPS® 3 ND System is more than a capital expenditure—it completes the cardiovascular team. Reach out to our team today to get more information and schedule a demo.
References
* The Quest MPS3 ND System elimiinates the need for disinfecting the internal water circuit. With the Quest MPS3 ND System, only exterior surfaces of the device need disinfection. Refer to the Quest MPS3 ND operations manual for exterior surface disinfection instructions
1 Disinfecting Costs; Data on file
2 https://www.cdc.gov/hai/outbreaks/heater-cooler.html
3 Estimating the Additional Hospital Inpatient Cost and Mortality Associated With Selected Hospital-Acquired Conditions. Content last reviewed November 2017. Agency for Healthcare Research and Quality, Rockville, MD
4 Data collected from Clinical Study: Marc W Gerdisch, et al. Clinical and economic benefits of advanced microplegia delivery system in cardiac surgery: evidence from 250 hospitals. Journal of Comparative Effectiveness Research 2018; April: 673-683
5 Bharat Datt, CCP, ert al. Blood Only Cardioplegia with Quest MPS, Canadian Perfusion Canadienne 2009; 19(1) April: 31-37
6 Algani KD, MD, MHS, et al. Microplegia during coronary artery bypass grafting was associated with less low cardiac output syndrome: a propensity-matched comparison. Ann Thorac Surg. 2013 May;95(5):1532-8. doi:10/1016/j.athoracsur.2012.09.056
7 Marc W Gerdisch, et al. Clinical and economic benefits of advanced microplegia delivery system in cardiac surgery: evidence from 250 hospitals. Journal of Comparative Effectiveness Research 2018; April: 673-683
For complete indications, contraindications, warnings, precautions, and potential adverse events, refer to the product's Instructions for Use (IFU).